“Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s422. doi:10.25251/skin.8.supp.422.